CN114008047A - 作为XIa因子抑制剂的大环衍生物 - Google Patents
作为XIa因子抑制剂的大环衍生物 Download PDFInfo
- Publication number
- CN114008047A CN114008047A CN202080047754.6A CN202080047754A CN114008047A CN 114008047 A CN114008047 A CN 114008047A CN 202080047754 A CN202080047754 A CN 202080047754A CN 114008047 A CN114008047 A CN 114008047A
- Authority
- CN
- China
- Prior art keywords
- compound
- isomer
- pharmaceutically acceptable
- acceptable salt
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
大环衍生物、其制备方法及含有该衍生物的药物组合物,以及它们作为治疗剂,特别是作为XIa因子抑制剂和在治疗和预防血栓栓塞等疾病的药物中的用途,具体公开了式(I)所示化合物、其异构体及其药学上可接受的盐。
Description
PCT国内申请,说明书已公开。
Claims (27)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910668575 | 2019-07-23 | ||
CN2019106685753 | 2019-07-23 | ||
PCT/CN2020/103692 WO2021013209A1 (zh) | 2019-07-23 | 2020-07-23 | 作为XIa因子抑制剂的大环衍生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114008047A true CN114008047A (zh) | 2022-02-01 |
CN114008047B CN114008047B (zh) | 2023-03-21 |
Family
ID=74193271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080047754.6A Active CN114008047B (zh) | 2019-07-23 | 2020-07-23 | 作为XIa因子抑制剂的大环衍生物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220281868A1 (zh) |
EP (1) | EP4006029A4 (zh) |
JP (1) | JP7286001B2 (zh) |
CN (1) | CN114008047B (zh) |
WO (1) | WO2021013209A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220144836A1 (en) * | 2019-04-11 | 2022-05-12 | Bristol-Myers Squibb Company | Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106459051A (zh) * | 2014-01-31 | 2017-02-22 | 百时美施贵宝公司 | 含杂环基团的大环fxia抑制剂 |
CN106795161A (zh) * | 2014-10-01 | 2017-05-31 | 百时美施贵宝公司 | 作为因子xia抑制剂的嘧啶酮 |
WO2018133793A1 (zh) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2789622C (en) | 2010-02-11 | 2018-04-03 | Bristol-Myers Squibb Company | Macrocycles as factor xia inhibitors |
TW201319068A (zh) * | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
LT2882734T (lt) | 2012-08-03 | 2016-12-12 | Bristol-Myers Squibb Company | Dihidropiridonai, kaip xia faktoriaus slopikliai |
DK2880026T3 (en) * | 2012-08-03 | 2017-06-06 | Bristol Myers Squibb Co | DIHYDROPYRIDON-P1 AS A FACTOR XIA INHIBITORS |
JP6464176B2 (ja) | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 芳香族p2’基を有する第xia因子阻害剤としてのマクロ環 |
US10344039B2 (en) | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
JP6892858B2 (ja) * | 2015-10-29 | 2021-06-23 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 第XIa因子阻害剤 |
-
2020
- 2020-07-23 JP JP2022504257A patent/JP7286001B2/ja active Active
- 2020-07-23 CN CN202080047754.6A patent/CN114008047B/zh active Active
- 2020-07-23 US US17/629,117 patent/US20220281868A1/en active Pending
- 2020-07-23 EP EP20844870.4A patent/EP4006029A4/en active Pending
- 2020-07-23 WO PCT/CN2020/103692 patent/WO2021013209A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106459051A (zh) * | 2014-01-31 | 2017-02-22 | 百时美施贵宝公司 | 含杂环基团的大环fxia抑制剂 |
CN106795161A (zh) * | 2014-10-01 | 2017-05-31 | 百时美施贵宝公司 | 作为因子xia抑制剂的嘧啶酮 |
WO2018133793A1 (zh) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
Also Published As
Publication number | Publication date |
---|---|
US20220281868A1 (en) | 2022-09-08 |
CN114008047B (zh) | 2023-03-21 |
WO2021013209A1 (zh) | 2021-01-28 |
JP7286001B2 (ja) | 2023-06-02 |
EP4006029A4 (en) | 2023-06-21 |
EP4006029A1 (en) | 2022-06-01 |
JP2022541927A (ja) | 2022-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI520965B (zh) | 作為因子xia抑制劑之巨環類 | |
TW201620900A (zh) | 1,3-苯并二呃衍生物 | |
TW201713665A (zh) | 適用於治療與ntrk相關之病症的化合物及組合物 | |
EP3862348A1 (en) | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | |
TW201410667A (zh) | 二氫吡啶酮p1作爲凝血因子xia抑制劑 | |
TW201321379A (zh) | 吡唑并喹啉(Pyrazoloquinoline)衍生物 | |
CN109843872A (zh) | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 | |
TW201938556A (zh) | 化合物及它們在治療癌症中之用途 | |
CN114174282A (zh) | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 | |
EP3124486B1 (en) | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof | |
TW200811135A (en) | NK-1 and serotonin transporter inhibitors | |
CN114008047B (zh) | 作为XIa因子抑制剂的大环衍生物 | |
TW202317097A (zh) | 戊二醯亞胺類化合物與其應用 | |
WO2019192533A1 (zh) | 用于治疗乳腺癌的雌激素受体降解剂 | |
JP7292588B2 (ja) | Ccr2/ccr5アンタゴニストとしてのヘテロシクロアルキル系化合物 | |
CN113677682A (zh) | 作为XIa因子抑制剂的大环衍生物 | |
WO2019085996A1 (zh) | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 | |
HUE029636T2 (en) | Ariletinil derivatives | |
CN115003672A (zh) | 喹啉并咪唑类化合物及其应用 | |
CN114026079A (zh) | 一种sglt2/dpp4抑制剂及其应用 | |
Chen et al. | Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency | |
CN111808105A (zh) | 含有并环基团的嘧啶酮并吡唑类化合物、其制备方法及用途 | |
TWI839738B (zh) | 含氮雜環化合物、其製備方法及應用 | |
TWI813106B (zh) | 雄性激素受體結合分子及其用途 | |
TW202413366A (zh) | 含氮雜環化合物作為泛素-特異性蛋白酶1抑制劑的製備方法、應用及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40062027 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |